Varicella-zoster virus infections in immunocompromised patients - a single centre 6-years analysis

BMC Pediatrics

Matthias Eyrich¹  Paul G Schlegel¹  Johannes Liese⁴  Hermann J Girschick⁴  Stefan Gattenlöhner⁵  Benedikt Weissbrich²  Meinrad Beer³  Judith Schick¹  Verena Wiegering¹ 

[1]Dept. of Pediatric Hematology-Oncology, Pediatric Stem Cell Transplantation Program, University Children's Hospital Wuerzburg, Germany

[2]Institute for Virology and Immunbiology, University of Wuerzburg, Germany

[3]Dept. of Pediatric Radiology, University of Wuerzburg, Germany

[4]Dept. of Pediatric Infectious Diseases, Immunology and Rheumatology, University Children's Hospital Wuerzburg, Germany

[5]Dept. of Pathology, University of Wuerzburg, Germany

关键词: cidofovir;    pediatrics;    immunosuppression;    varicella-zoster virus;   

Others  :  1172178
DOI  :  10.1186/1471-2431-11-31

 received in 2010-07-28, accepted in 2011-05-10,  发布年份 2011

【 摘 要 】

Background

Infection with varicella-zoster virus (VZV) contemporaneously with malignant disease or immunosuppression represents a particular challenge and requires individualized decisions and treatment. Although the increasing use of varicella-vaccines in the general population and rapid initiation of VZV-immunoglobulins and acyclovir in case of exposure has been beneficial for some patients, immunocompromised individuals are still at risk for unfavourable courses.

Methods

In this single center, 6-year analysis we review incidence, hospitalization and complication rates of VZV-infections in our center and compare them to published data. Furthermore, we report three instructive cases.

Results

Hospitalization rate of referred children with VZV-infections was 45%, among these 17% with malignancies and 9% under immunosuppressive therapy. Rate of complications was not elevated in these two high-risk cohorts, but one ALL-patient died due to VZV-related complications. We report one 4-year old boy with initial diagnosis of acute lymphoblastic leukemia who showed a rapidly fatal outcome of his simultaneous varicella-infection, one 1.8-year old boy with an identical situation but a mild course of his disease, and an 8.5-year old boy with a steroid-dependent nephrotic syndrome. This boy developed severe hepatic involvement during his varicella-infection but responded to immediate withdrawl of steroids and administration of acyclovir plus single-dose cidofovir after nonresponse to acyclovir after 48 h.

Conclusion

Our data show that patients with malignant diseases or immunosuppressive therapy should be hospitalized and treated immediately with antiviral agents. Despite these measures the course of VZV-infections can be highly variable in these patients. We discuss aids to individual decision-making for these difficult situations.

【 授权许可】

   
2011 Wiegering et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Liese JG, Grote V, Rosenfeld E, Fischer R, Belohradsky BH, v Kries R: The burden of varicella complications before the introduction of routine varicella vaccination in Germany. Pediatr Infect Dis J 2008, 27(2):119-124.
• [2]Rack AL, Grote V, Streng A, Belohradsky BH, Heinen F, von Kries R, Liese JG: Neurologic varicella complications before routine immunization in Germany. Pediatr Neurol 2010, 42(1):40-48.
• [3]Feldman S, Hughes WT, Daniel CB: Varicella in children with cancer: Seventy-seven cases. Pediatrics 1975, 56(3):388-397.
• [4]Katsimpardi K, Papadakis V, Pangalis A, Parcharidou A, Panagiotou JP, Soutis M, Papandreou E, Polychronopoulou S, Haidas S: Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment. Support Care Cancer 2006, 14(3):277-284.
• [5]Matsuzaki A, Suminoe A, Koga Y, Kusuhara K, Hara T, Ogata R, Sata T: Fatal visceral varicella-zoster virus infection without skin involvement in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2008, 25(3):237-242.
• [6]Meir HM, Balawi IA, Meer HM, Nayel H, Al-Mobarak MF: Fever and granulocytopenia in children with acute lymphoblastic leukemia under induction therapy. Saudi Med J 2001, 22(5):423-427.
• [7]Dits H, Frans E, Wilmer A, Van Ranst M, Fevery J, Bobbaers H: Varicella-zoster virus infection associated with acute liver failure. Clin Infect Dis 1998, 27(1):209-210.
• [8]Muller I, Aepinus C, Beck R, Bultmann B, Niethammer D, Klingebiel T: Noncutaneous varicella-zoster virus (VZV) infection with fatal liver failure in a child with acute lymphoblastic leukemia (ALL). Med Pediatr Oncol 2001, 37(2):145-147.
• [9]Snoeck R, Andrei G, De Clercq E: Novel agents for the therapy of varicella-zoster virus infections. Expert Opin Investig Drugs 2000, 9(8):1743-1751.
• [10]De Clercq E: Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003, 16(4):569-596.
• [11]Folatre I, Zolezzi P, Schmidt D, Marin F, Tager M: [Infections caused by Varicella Zoster virus in children with cancer aged less than 15 years old]. Rev Med Chil 2003, 131(7):759-764.
• [12]Morfin F, Frobert E, Thouvenot D: [Contribution of the laboratory in case of resistance to acyclovir of herpes simplex and varicella zoster virus]. Ann Biol Clin (Paris) 2003, 61(1):33-40.
• [13]Rowland P, Wald ER, Mirro JR Jr, Yunis E, Albo VC, Wollman MR, Blatt J: Progressive varicella presenting with pain and minimal skin involvement in children with acute lymphoblastic leukemia. J Clin Oncol 1995, 13(7):1697-1703.
• [14]Ljungman P, Ribaud P, Eyrich M, Matthes-Martin S, Einsele H, Bleakley M, Machaczka M, Bierings M, Bosi A, Gratecos N, et al.: Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003, 31(6):481-486.
• [15]Andrei G, De Clercq E, Snoeck R: In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir? Antiviral Res 2004, 61(3):181-187.
• [16]Ventura GJ, Hester JP, Smith TL, Keating MJ: Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol 1988, 27(1):34-37.
• [17]Siedler A, Arndt U: Impact of the routine varicella vaccination programme on varicella epidemiology in Germany. Euro Surveill 2010., 15(13)